EHA 2026 preview – a Monumental boost to J&J’s Talvey hopes
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
J&J tries to outdo Tecvayli
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
J&J claims a Tecvayli/Darzalex combo win
The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.
A new multiple myeloma race heats up
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
Sino takes out the rest of Merck’s partner
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
EHA 2025 – J&J claims an extramedullary edge
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.
ASCO 2025 – J&J challenges its own multiple myeloma T-cell engagers
Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.
